No connection

Search Results

AAPG vs AHG

AAPG
Ascentage Pharma Group Internat
BEARISH
Price
$22.32
Market Cap
$2.09B
Sector
Healthcare
AI Confidence
85%
AHG
Akso Health Group
BEARISH
Price
$2.50
Market Cap
$2.14B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
AAPG
--
AHG
--
Forward P/E
AAPG
-46.43
AHG
--
P/B Ratio
AAPG
79.25
AHG
10.82
P/S Ratio
AAPG
5.35
AHG
144.3
EV/EBITDA
AAPG
-7.41
AHG
-4387.63

Profitability

Gross Margin
AAPG
90.87%
AHG
1.0%
Operating Margin
AAPG
-237.05%
AHG
-20.54%
Profit Margin
AAPG
-296.77%
AHG
0.0%
ROE
AAPG
-159.65%
AHG
-68.29%
ROA
AAPG
-22.77%
AHG
-1.42%

Growth

Revenue Growth
AAPG
-71.6%
AHG
0.9%
Earnings Growth
AAPG
--
AHG
--

Financial Health

Debt/Equity
AAPG
2.54
AHG
0.01
Current Ratio
AAPG
1.54
AHG
1.53
Quick Ratio
AAPG
1.4
AHG
1.19

Dividends

Dividend Yield
AAPG
--
AHG
--
Payout Ratio
AAPG
0.0%
AHG
0.0%

AI Verdict

AAPG BEARISH

AAPG's Piotroski F-Score of 4/9 indicates weak financial health, with no Altman Z-Score available to assess bankruptcy risk. The company exhibits severe profitability issues, with a negative profit margin of -296.77% and ROE of -159.65%, alongside a 71.6% YoY revenue decline. Despite a high gross margin of 90.87%, the business is not generating sustainable earnings. The stock trades at a premium valuation (Price/Book: 79.25) with no intrinsic value or Graham Number, suggesting speculative pricing. Analysts rate it a 'strong_buy' with a target of $49.14, but this is not supported by fundamentals.

Strengths
High gross margin of 90.87% indicates strong product-level pricing power or cost control
Analyst consensus is 'strong_buy' with a significant target price upside of ~120%
Recent 1-year return of +17.7% shows some market momentum despite fundamentals
Risks
Piotroski F-Score of 4/9 signals weak financial health and deteriorating operational efficiency
Negative profit margin (-296.77%) and ROE (-159.65%) indicate severe unprofitability
71.6% YoY revenue decline reflects a shrinking business model or failed product pipeline
AHG BEARISH

AHG's Piotroski F-Score of 5/9 indicates a stable but not strong financial position, with significant red flags in profitability and cash flow. The company reports a 0.00% profit margin, negative ROE of -68.29%, and a gross margin of just 1.00%, signaling deep operational inefficiencies. Despite a low debt/equity ratio and decent liquidity, the absence of positive earnings, free cash flow, and a lack of dividend support undermine long-term sustainability. The stock's price performance is driven by speculative momentum rather than fundamentals, with a Price/Sales of 144.30 far exceeding sector averages and no intrinsic value support.

Strengths
Low debt/equity ratio (0.01) indicates minimal financial leverage risk
Current ratio of 1.53 and quick ratio of 1.19 suggest adequate short-term liquidity
Recent price surge (85.2% in 1 week) reflects strong short-term market momentum
Risks
Negative ROE (-68.29%) and ROA (-1.42%) indicate severe capital inefficiency and losses
0.00% profit margin and -20.54% operating margin reveal fundamental business model flaws
No free cash flow or operating cash flow data available, raising liquidity sustainability concerns

Compare Another Pair

AAPG vs AHG: Head-to-Head Comparison

This page compares Ascentage Pharma Group Internat (AAPG) and Akso Health Group (AHG) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile